Lorenzo Emiliano Imbò

Mr. Lorenzo Emiliano Imbò


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Molecules
Verified
Journal Article
Open access
PDF file
OAOluwasegun Eric Ajayi
Oluwasegun Eric Ajayi
Rosa BellavitaRosa Bellavita
Rosa Bellavita
Lorenzo Emiliano ImbòLorenzo Emiliano Imbò
Lorenzo Emiliano Imbò
SPSara Palladino
Sara Palladino
SBSimone Braccia
Simone Braccia
Stefania GaldieroStefania Galdiero
Stefania Galdiero
Antimicrobial peptides (AMPs) represent a powerful support to conventional antibiotics in addressing the global challenge of antimicrobial resistance (AMR). Their broad-spectrum antimicrobial activity and unique mechanisms of action enable diverse potential applications, including combating multidrug-resistant pathogens, immune modulation, and cancer therapy. Their clinical implementation is hindered by challenges such as toxicity, instability, and high production costs. Recent advances in AMP design, optimization, and delivery mechanisms such as nanoparticle conjugation and rational engineering have enhanced their efficacy, stability, and specificity. Integrating AMPs into precision medicine and combining them with existing therapies promises to overcome current limitations. With ongoing advancements, AMPs have the potential to redefine infection management and possibly other medical problems.

10 September 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Rosa BellavitaRosa Bellavita
Rosa Bellavita
SPSara Palladino
Sara Palladino
KRKaryne Rangel
Karyne Rangel
GLGuilherme Lechuga
Guilherme Lechuga
Lorenzo Emiliano ImbòLorenzo Emiliano Imbò
Lorenzo Emiliano Imbò
Annarita FalangaAnnarita Falanga
Annarita Falanga
Background/Objectives: Temporizin-1, a hybrid antimicrobial peptide derived from the combination of Temporin A, Gramicidin peptide, and a poly-leu sequence, has strong trypanocide activity against Trypanosoma cruzi and moderate cytotoxicity towards mammalian cells. In this study, we investigated the mode of action of the peptide upon interaction with protozoan and eukaryotic membranes. Methods: To this end, we conducted a series of biophysical assays using liposomes as biomimetic models, along with fluorescence-based experiments such as lipid mixing, membrane leakage, and assays involving Thioflavin and Laurdan. Results: Temporizin-1 displayed potent membranolytic activity on protozoan and eukaryotic membranes, causing significant membrane fusion and leakage with consequent pore formation. In addition, we also performed structural studies on liposome interaction, where we observed a helical structure that is conserved during membrane interaction. The NMR study confirms all the data obtained, providing both the structure of free Temporizin-1 in solution and the way it interacts with micelles. Moreover, Temporizin-1 demonstrated high selectivity against intracellular forms of T. cruzi and exhibited an additive effect when combined with benznidazole, highlighting its promising therapeutic activity. Conclusions: In conclusion, elucidating the mechanism of action of Temporizin-1 is essential for optimizing its structure and improving target selectivity, and driving the rational design of next-generation antimicrobial peptides by applying chemical strategies and delivery system’s conjugation.